Last reviewed · How we verify
Conventional Synthetic DMARD
Conventional synthetic DMARDs suppress immune system activity through inhibition of inflammatory pathways to reduce joint inflammation and slow disease progression in rheumatoid arthritis.
Conventional synthetic DMARDs suppress immune system activity through inhibition of inflammatory pathways to reduce joint inflammation and slow disease progression in rheumatoid arthritis. Used for Rheumatoid arthritis.
At a glance
| Generic name | Conventional Synthetic DMARD |
|---|---|
| Also known as | Background therapy with conventional synthetic DMARD |
| Sponsor | SetPoint Medical Corporation |
| Drug class | Conventional synthetic DMARD |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Conventional synthetic DMARDs (disease-modifying antirheumatic drugs) work by broadly suppressing T-cell and B-cell activation and reducing production of pro-inflammatory cytokines. SetPoint Medical's approach in this class typically involves modulation of immune responses to achieve anti-inflammatory effects. These agents target multiple steps in the inflammatory cascade rather than a single specific molecular target.
Approved indications
- Rheumatoid arthritis
Common side effects
- Hepatotoxicity
- Myelosuppression
- Gastrointestinal disturbances
- Infection
Key clinical trials
- Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
- At-home Ultrasound Localized Therapy for Rheumatoid Arthritis Study [At-home ULTRA Study] (NA)
- Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis (PHASE3)
- Proximod, a Selective Sphingosine-1-phosphate Receptor 1 Modulator in Patients With Moderate-to-severe Active Rheumatoid Arthritis: a Double-blind, Randomised, Placebo-controlled, Phase 2 Trial. (PHASE2)
- The Effect of Cilostazol on Rheumatoid Arthritis Patients (PHASE2, PHASE3)
- Nerve Conduction Study for Assessment of Peripheral Neuropathy in Rheumatoid Arthritis Patients on the Janus Kinase Inhibitor Baricitinib (NA)
- Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis. (PHASE4)
- A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |